Fidelity Advisor Biotechnology M (FBTTX)

Fund Assets	2.43B
Expense Ratio	1.201%
Min. Investment	$0.00
Turnover	54.00%
Dividend (ttm)	0.42
Dividend Yield	0.97%
Dividend Growth	-43.52%
Payout Frequency	Annual
Ex-Dividend Date	Dec 26, 2025

Previous Close	42.35
YTD Return	28.10%
1-Year Return	41.85%
5-Year Return	65.08%
52-Week Low	31.40
52-Week High	47.32
Beta (5Y)	0.84
Holdings	131
Inception Date	Dec 27, 2000

About FBTTX

Fidelity Advisor Biotechnology Fund - Class M is a mutual fund specializing in the biotechnology sector. Its primary objective is capital appreciation by investing at least 80% of its assets in companies that are primarily engaged in the research, development, manufacture, and distribution of biotechnology products, services, and processes, or those significantly benefiting from advances in biotechnology. The fund offers exposure to a range of both established and innovative biotech firms, with significant holdings in leading healthcare companies such as AbbVie, Gilead Sciences, and Amgen. With portfolio assets exceeding $1.3 billion, the fund is positioned as a focused vehicle for investors seeking diversified access to the growth and innovation of the biotech industry. It is managed by Fidelity Investments, known for its research-driven approach and strong management team. The fund plays a key role in the market for those aiming to participate in the dynamic and rapidly evolving biotechnology sector, which is instrumental in driving advancements across healthcare and pharmaceuticals.

• Fund Family: Fidelity
• Category: Health
• Performance Rating: High
• Risk Rating: Above Average
• Stock Exchange: Nasdaq
• Ticker Symbol: FBTTX
• Share Class: Class M
• Index: S&P 500 TR

Performance

FBTTX had a total return of 41.85% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.37%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FIJYX	Class Z	0.57%
FBTIX	Class I	0.69%
FBTAX	Class A	0.94%
FBTCX	Class C	1.69%

Top 10 Holdings

46.21% of assets

Name	Symbol	Weight
AbbVie Inc.	ABBV	13.83%
Gilead Sciences, Inc.	GILD	6.02%
Alnylam Pharmaceuticals, Inc.	ALNY	3.84%
Insmed Incorporated	INSM	3.41%
Amylyx Pharmaceuticals, Inc.	AMLX	3.38%
argenx SE	ARGX	3.28%
Dianthus Therapeutics, Inc.	DNTH	3.18%
Spyre Therapeutics, Inc.	SYRE	3.16%
Moderna, Inc.	MRNA	3.12%
Revolution Medicines, Inc.	RVMD	2.98%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 26, 2025	$0.521	Dec 29, 2025
Dec 26, 2024	$1.586	Dec 27, 2024
Dec 21, 2023	$0.234	Dec 22, 2023
Dec 17, 2021	$5.318	Dec 20, 2021
Jul 9, 2021	$0.070	Jul 12, 2021
Dec 18, 2020	$2.779	Dec 21, 2020

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Nov 9, 2026

Data Sources Report a data error